Who are Evofem Biosciences's investors?

Evofem Biosciences's investors include Adjuvant Capital, Domain Associates, Invesco, Woodford Investment Management.

How much funding has Evofem Biosciences raised?

Evofem Biosciences has disclosed $85.6M raised across 11 of its 12 known rounds.

Where is Evofem Biosciences headquartered?

Evofem Biosciences is headquartered in San Diego, US.

Evofem Biosciences

OTC: EVFM

San Diego, US · Founded 2015 · Delaware corporation · 40 employees on LinkedIn · 4 known investors

Find your way into Evofem Biosciences

804 people in our graph share verified history with the Evofem Biosciences team — schools, employers, funds. One of them is your warm intro.

Josh Riezmanunlockedknows Justin J. File · together at Lite Strategy (overlapped)

knows the team · via Women Corporate Directors Foundation

×6knows the team · via Virginia Tech

×3knows the team · via University of Victoria

knows the team · via Evofem Biosciences

Evofem Biosciences is a biopharmaceutical company that commercializes products for women's sexual and reproductive health, including PHEXX, a non-hormonal prescription vaginal contraceptive gel applied before intercourse, and SOLOSEC, an oral antimicrobial agent for treating bacterial vaginosis and trichomoniasis. The company markets these products in the United States and pursues international expansion through licensing partnerships.

Biotech

Founders & leadership

Ivy Zhang ExecutiveIvy Zhang is an executive officer at Evofem Biosciences with audit experience across biotech, life sciences, energy, engineering, wireless technology, and private equity sectors.

Saundra Pelletier ExecutiveSaundra Pelletier is CEO of Evofem Biosciences, a commercial-stage biopharmaceutical company that develops and markets products for women's sexual and reproductive health, including the non-hormonal contraceptive gel PHEXX and the antimicrobial agent SOLOSEC for treating vaginal infections.

Kelly Culwell ExecutiveKelly Culwell is an Executive Officer at Evofem Biosciences, a biopharmaceutical company commercializing women's reproductive health products. She holds a medical degree with specialty training in family planning and previously served as a medical officer for the World Health Organization, developed a family planning fellowship program at the University of California, Davis, and held leadership roles in pharmaceutical companies bringing contraceptive products through FDA approval.

Justin J. File ExecutiveJustin File is an executive officer at Evofem Biosciences with approximately 30 years of experience in accounting and finance, including roles supporting early-stage biotechnology companies through IPOs and follow-on capital raises, as well as publicly traded biotech entities in expanding operations. He has expertise in corporate accounting, finance, investor relations, IT management, and SEC reporting compliance.

Alexander A. FitzpatrickExecutive

Russell BarransExecutive

William HallNamed on SEC filing

Thomas LynchNamed on SEC filing

Board

Kim Kamdar Board directorPromoter at Medical Excellence Capital

Colin RutherfordBoard director

Lisa RarickBoard director

Tony O'BrienBoard director

Investors · 4

Adjuvant CapitalreportedNew York · $10M – $25M

How we know: a partner's Signal profile · Not right? Tell us

Domain AssociatesinferredPrinceton · $200K – $15Mvia Kim Kamdar · board

How we know: board seat on SEC Form D · Not right? Tell us

InvescoreportedAtlanta

How we know: the S-1 prospectus · Not right? Tell us

Woodford Investment ManagementreportedOxford

How we know: the S-1 prospectus · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$85.6M disclosed across 11 of 12 rounds · 1900–2025

▶$925KraisedJul 2025 · 1 investors · Biotechnology

Rule 506(b)